Table 4 Comparisons of on-Tg with TgAb-negative and RAI administration
On-Tg ≥ 0.2 ng/ml (N = 30) | On-Tg < 0.2 ng/ml (N = 13) | t/χ2 | P | |
|---|---|---|---|---|
Age, yrs | 47.2 ± 14.5 | 38.0 ± 14.2 | − 1.917 | 0.062 |
Sex (male) | 12 | 4 | 0.054 | 0.817 |
BMI | 23.4 ± 3.5 | 22.9 ± 3.3 | − 0.417 | 0.679 |
NG | 13 | 6 | 0.029 | 0.864 |
HD | 4 | 1 | < 0.001 | 0.990 |
Hypertension | 3 | 1 | < 0.001 | 1.000 |
Diabetes | 1 | 1 | – | 0.518 |
Hyperthyroidism | 2 | 0 | – | 1.000 |
Tumor size (primary), mm | 22.6 ± 14.0 | 19.9.0 ± 11.8 | − 0.594 | 0.556 |
Multifocality (primary) | 2 | 5 | 4.597 | 0.032* |
Bilatrality (primary) | 2 | 2 | 0.110 | 0.740 |
Surgical strategy | ||||
iCND | 0 | 0 | – | – |
bCND | 6 | 3 | – | – |
bCND + iLND | 17 | 9 | – | 0.385 |
bCND + bLND | 7 | 1 | – | 0.385 |
Harvested LNs | 38.4 ± 20.5 | 36.3 ± 22.3 | − 0.300 | 0.766 |
Metastatic LNs | 10.9 ± 9.4 | 6.2 ± 7.4 | − 1.588 | 0.120 |
The ratio of metastatic LNs % | 29.9 ± 24.0 | 19.1 ± 14.4 | − 1.500 | 0.141 |
Diameter of recurrent LNs | 23.6 ± 15.5 | 16.0 ± 4.7 | − 2.438 | 0.020* |
≥ 25 mm | 13 | 0 | 6.151 | 0.013* |
Extranodal extension | 11 | 6 | 0.341 | 0.559 |